重症监护病房患者耳念珠菌感染:危险因素、结局与抗真菌耐药模式
这项在印度东部一家三级医院ICU开展的回顾性队列研究(2020年1月至2023年12月)纳入267例培养确诊念珠菌血症的成人患者,其中38例(14.2%)为耳念珠菌感染。多因素分析显示,年龄增长(OR 1.10)和女性(OR 16.35)与耳念珠菌感染独立相关。耳念珠菌分离株对氟康唑耐药率为94.7%,对两性霉素B和棘白菌素耐药率分别为39.5%和7.9%。耳念珠菌组与非耳念珠菌组ICU死亡率无显著差异(31.6% vs 34.5%,p=0.854),生存分析亦无统计学显著差异(log-rank p=0.07)。作者认为,在耳念珠菌流行地区需持续监测并针对性评估风险。
要点
- ICU念珠菌血症患者中耳念珠菌占14.2%(38/267),提示在该流行地区需将耳念珠菌纳入经验性抗真菌覆盖的考量。
- 耳念珠菌感染独立危险因素为年龄增长(OR 1.10,p=0.0003)和女性(OR 16.35,p=0.012)。
- 耳念珠菌分离株氟康唑耐药率94.7%,两性霉素B耐药率39.5%,棘白菌素耐药率7.9%。
- 耳念珠菌组与非耳念珠菌组ICU死亡率无显著差异(31.6% vs 34.5%,p=0.854),生存分析log-rank p=0.07。
- 作者认为在耳念珠菌流行地区需持续监测并针对性评估风险。
适用人群与场景
- 印度东部一家三级医院ICU的成人患者(≥18岁),2020年1月至2023年12月期间培养确诊念珠菌血症。
研究设计与关键结果
- 回顾性队列研究,纳入267例ICU念珠菌血症成人患者,耳念珠菌组38例(14.2%),非耳念珠菌组229例。
- 耳念珠菌组中位年龄60岁 vs 非耳念珠菌组53岁;入院SOFA评分中位数7 vs 8(p=0.02)。
- 多因素分析:年龄增长(OR 1.10,p=0.0003)和女性(OR 16.35,p=0.012)与耳念珠菌感染独立相关。
- 耳念珠菌分离株氟康唑耐药率94.7%,两性霉素B耐药率39.5%,棘白菌素耐药率7.9%。
- ICU死亡率耳念珠菌组31.6% vs 非耳念珠菌组34.5%(p=0.854),无显著差异;生存分析log-rank p=0.07。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在耳念珠菌流行地区的ICU,对高龄和女性念珠菌血症患者应提高对耳念珠菌的警惕,并依据本地的耐药谱(氟康唑耐药率94.7%)选择抗真菌药物。
- 耳念珠菌感染并未增加ICU死亡率(31.6% vs 34.5%,p=0.854),但作者认为需持续监测并针对性评估风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Candida auris has emerged as a major nosocomial pathogen in intensive care units worldwide due to its multidrug resistance, environmental persistence, and high transmission potential. While several outbreak reports exist, there remains limited comparative data on clinical features, resistance profiles, and outcomes between Candida auris and non-auris Candida candidemia, particularly in Indian ICU settings. This study aimed to evaluate the incidence, risk factors, antifungal resistance, and clinical outcomes of Candida auris bloodstream infections in comparison to non-auris Candida infections among ICU patients. METHODS: This retrospective cohort study was conducted over four years (January 2020–December 2023) in the ICU of a tertiary care hospital in eastern India. Adult patients (≥ 18 years) with culture-confirmed candidemia were included and stratified into Candida auris and non-auris groups. Demographic, clinical, therapeutic, and microbiological data were extracted. Antifungal susceptibility testing was performed as per CLSI and CDC guidelines. Multivariate logistic regression identified risk factors associated with Candida auris infection. Survival analysis were compared using Kaplan–Meier and Cox regression analysis. RESULTS: Of 267 ICU patients with candidemia, 38 (14.2%) had Candida auris infection. Candida auris patients were older (median age 60 vs. 53 years) and had lower SOFA scores at admission (median 7 vs. 8; p = 0.02). On multivariate analysis, increasing age (OR 1.10, p = 0.0003) and female sex (OR 16.35, p = 0.012) were independently associated with Candida auris infection. Fluconazole resistance was 94.7% in Candida auris isolates, with amphotericin B and echinocandin resistance in 39.5% and 7.9%, respectively. ICU mortality did not differ significantly between Candida auris and non-auris groups (31.6% vs. 34.5%; p = 0.854), and survival analysis showed no statistically significant difference (log-rank p = 0.07). CONCLUSION: This study highlights the growing burden of Candida auris in intensive care unit settings, demonstrating a substantial incidence without increased mortality compared to non-auris Candida species. Advancing age and female sex emerged as significant independent risk factors, emphasizing the need for continued surveillance and targeted risk assessment in regions where Candida auris is endemic.
参考来源
- Choudhury S, Majhi K, Jena P, et al. Candida auris infections in ICU patients: risk factors, outcomes, and antifungal resistance patterns. Crit Care. 2025. PMID: 40722190. doi:10.1186/s13054-025-05544-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。